Quick-dissolving microneedle patch capable of improving male hormonal alopecia as well as preparation method and application of quick-dissolving microneedle patch
By developing microneedle patches covering liposome nanoparticles with ginseng saponin CK and nitrosoglutathione, the limitations of existing androgenic hair loss treatment methods have been solved, and the microenvironment of hair papillary cells has been realized. Effective drug release improves the hair follicle microenvironment and hair papillary cell activity, and significantly improves the therapeutic effect of androgenic hair loss.
Patent Information
- Application Number
- CN202411357600.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-27
- Publication Date
- 2024-12-03
AI Technical Summary
Existing treatments for androgenic alopecia, such as minoxidil and finasteride, have limitations, such as skin irritation and potential erectile dysfunction, and lack effective novel treatments with good efficacy.
A rapid dissolution microneedle patch was developed with the needle tip partially coated with liposome nanoparticles loaded with ginsenoside CK and nitrosoglutathione through the lipids loaded with ginsenoside CK and nitrosoglutathione. The plastid solution is mixed with polyvinyl alcohol solution to prepare a microneedle patch that penetrates the epidermis and slowly releases the drug in the microenvironment of hair papillary cells.
This microneedle patch can effectively reduce patient pain, penetrate less than 750μM and almost no bleeding. The drug can quickly dissolve and slowly release it into the microenvironment of hair nipple cells, improve the hair follicle microenvironment, promote angiogenesis, and improve hair nipple. Cell activity significantly improves androgenic hair loss.
Smart Images

Figure CN119055582A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of biomedical materials, and in particular relates to a fast-dissolving microneedle patch capable of improving androgenic alopecia, and a preparation method and application thereof. Background Art
[0002] Hair is an important part of the integumentary system. Although hair loss problems are usually not life-threatening, they can have a negative impact on the patient's mental health. As one of the most common causes of hair loss, androgenetic alopecia (AGA) affects 53% of men and 30% of women. AGA has been confirmed to be a chronic disease, and throughout its pathophysiological process, the hair follicles under the scalp experience a variety of different stimuli. Usually overexpressed androgens trigger the body to produce large amounts of dihydrotestosterone (DHT), which attacks the hair follicles and causes them to gradually shrink. When the hair follicles are attacked, the hair follicle microenvironment will show abnormalities, such as excessive reactive oxygen species generation and microvascular damage, and the stem cells in the hair follicles around the attacked area are also suppressed away from the growth phase. Continuous attacks and delayed repair eventually lead to hair follicle necrosis and spread of hair loss. Therefore, AGA is a systemic disease caused by multiple factors, mainly including excessive androgen attack, excessive reactive oxygen species generation, and atrophy of large capillary damage.
[0003] Minoxidil (a vasodilator) and finasteride (an androgen inhibitor) are the most commonly used drugs for the treatment of AGA. However, both have certain limitations. For example, minoxidil may cause skin irritation such as itching and stinging, while long-term use of finasteride may cause erectile dysfunction in men. Therefore, it is necessary to consider the pathogenesis of AGA and develop new treatments that can effectively promote hair regeneration and have good efficacy and biocompatibility. Summary of the invention
[0004] The technical problem to be solved by the present invention is to provide a fast-dissolving microneedle patch that can improve androgenic alopecia, and its preparation method and application in view of the deficiencies of the above-mentioned prior art. The needle tip of the microneedle patch can reach the interstitial fluid, and after fast dissolution, slowly release ginsenoside CK and GSNO to reach the microenvironment where the hair papilla cells are located to play a role, thereby improving the hair follicle microenvironment and increasing the activity of the hair papilla cells that play a key role in androgenic alopecia.
[0005] In order to solve the above technical problems, the technical solution adopted by the present invention is: a fast-dissolving microneedle patch that can improve androgenic alopecia, characterized in that the needle tip portion of the microneedle patch is coated with liposome nanoparticles loaded with ginsenoside CK and nitrosoglutathione.
[0006] The above-mentioned fast-dissolving microneedle patch that can improve androgenic alopecia is characterized in that when the needle tip is coated with liposome nanoparticles loaded with ginsenoside CK and nitrosoglutathione, a mixed solution of a liposome solution loaded with ginsenoside CK and nitrosoglutathione and a polyvinyl alcohol solution is used as the needle tip preparation solution.
[0007] Furthermore, the present invention provides a method for preparing the above-mentioned fast-dissolving microneedle patch for improving androgenic alopecia, characterized in that it comprises the following steps:
[0008] Step 1, preparing a negative microneedle array mold;
[0009] Step 2, after dissolving lecithin and cholesterol, add ginsenoside CK to obtain a mixed solution; the concentration of ginsenoside CK in the mixed solution is 1 mg / mL to 4 mg / mL; the concentration of lecithin is 5 mg / mL to 20 mg / mL, and the concentration of cholesterol is 1 mg / mL to 5 mg / mL;
[0010] Step 3, transferring the mixed solution in step 2 into a round-bottom flask, rotary evaporating until a uniform film is formed at the bottom of the round-bottom flask, and then drying to evaporate trace amounts of organic solvent;
[0011] Step 4, dissolving nitrosoglutathione in PBS solution to obtain GSNO solution; then transferring the GSNO solution to the round-bottom flask dried in step 3 and hydrating in the dark, ultrasonically treating after hydration, filtering and centrifuging to remove undissolved ginsenoside CK and nitrosoglutathione that did not enter the hydrophilic cavity inside the liposome, and obtaining a liposome solution loaded with ginsenoside CK and nitrosoglutathione;
[0012] Step 5, mixing the liposome solution loaded with ginsenoside CK and nitrosoglutathione with the polyvinyl alcohol solution to obtain a needle tip preparation solution;
[0013] Step 6: Add the needle tip preparation solution in step 5 to the negative mold microneedle array mold in step 1, and use a vacuum pump to evacuate the mold so that the needle tip preparation solution fully enters the needle tip portion of the negative mold microneedle array mold;
[0014] Step 7: Suck out the excess needle tip preparation liquid except the needle tip, add polyvinyl alcohol solution to the negative mold to fill the empty part of the mold, then place it in an oven to dry, and demold to obtain a fast-dissolving microneedle patch that can improve androgenic alopecia.
[0015] The above method is characterized in that in step 2, lecithin and cholesterol are dissolved in a mixed solution of chloroform and anhydrous ethanol, and the volume ratio of chloroform to anhydrous ethanol is 1:(1-3).
[0016] The above method is characterized in that the temperature of the rotary evaporation in step three is 30°C to 45°C, the duration is 10min to 30min, and the vacuum drying oven is used for drying, and the drying time is 4h to 12h.
[0017] The above method is characterized in that the concentration of nitrosoglutathione in the GSNO solution in step 4 is 0.2 mg / mL to 1 mg / mL; the hydration condition is 30°C to 45°C for 20min to 40min; the ultrasonic time is 2min to 10min, the ultrasonic power is 300W to 500W, and the filtration uses a 220μM filter membrane.
[0018] The above method is characterized in that the mass percentage concentration of the polyvinyl alcohol solution in step five is 20% to 30%; the volume ratio of the liposome solution loaded with ginsenoside CK and nitrosoglutathione to the polyvinyl alcohol solution is 1:(50 to 80).
[0019] The above method is characterized in that the vacuum degree in step six is 30kPa to 70kPa.
[0020] The above method is characterized in that the total filling solution volume in step seven is 500 μL; the oven temperature is 30° C. to 45° C., and the drying time is 12 h to 24 h.
[0021] Furthermore, the present invention provides a use of the above-mentioned fast-dissolving microneedle patch for improving androgenic alopecia in the preparation of drugs and / or medical devices for improving the hair follicle microenvironment.
[0022] Compared with the prior art, the present invention has the following advantages:
[0023] 1. The microneedle patch of the present invention is a powerful transdermal drug delivery system. The needle tip of the microneedle patch is coated with liposome nanoparticles loaded with ginsenoside CK and nitrosoglutathione (GSNO). The needle tip can penetrate the epidermis and transport the drug to a certain skin depth. In addition, penetration less than 750 μM will hardly cause bleeding or pain, which can meet the basic drug delivery needs while reducing the patient's pain.
[0024] 2. The needle tip of the microneedle patch of the present invention can reach the interstitial fluid, dissolve rapidly and then slowly release ginsenoside CK and GSNO to reach the microenvironment of the hair papilla cells to exert their effects. GSNO can release NO, promote angiogenesis, and play an anti-inflammatory role.
[0025] 3. The main active ingredients of the microneedle patch of the present invention include ginsenoside CK and GSNO, among which ginsenoside CK is a natural product. CK has a high degree of safety and diverse biological functions and may be a potential therapeutic agent for many diseases. GSNO plays a key role in NO signal transduction in the human body and is a source of NO that can be bioavailable. After the drug reaches the microenvironment where the hair papilla cells are located, it can improve the hair follicle microenvironment and increase the activity of the hair papilla cells that play a key role in androgenic alopecia.
[0026] The technical solution of the present invention is further described in detail below in conjunction with the accompanying drawings and embodiments. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Figure 1 The diagram is a schematic diagram of the construction and use of the fast-dissolving microneedle patch for improving androgenic alopecia of the present invention.
[0028] Figure 2 Schematic diagram of the characterization of the encapsulation efficiency and drug loading rate of ginsenoside CK at different concentrations.
[0029] Figure 3 Schematic diagram of the dynamic light scattering nanoparticle size analysis results of the liposome solution loaded with ginsenoside CK and nitrosoglutathione prepared in Example 1 of the present invention and the morphology of the nanoparticles under an electron microscope.
[0030] Figure 4 This is a schematic diagram of the in vitro release results of the active ingredients in the liposome solution loaded with ginsenoside CK and nitrosoglutathione prepared in Example 1 of the present invention.
[0031] Figure 5 Schematic diagram of microneedle morphology and drug loading characterization.
[0032] Figure 6 The graphs show the results of cytotoxicity and cell proliferation.
[0033] Figure 7 Schematic diagram of hair coverage during the treatment phase of mice.
[0034] Figure 8 Schematic diagram of H&E staining results of treated mouse skin.
[0035] Fig. 9 Schematic diagram of the average hair diameter of each group of mice after treatment.
[0036] Fig.10 Schematic diagram of the toxicity analysis results of the five internal organs slices of each group of mice after treatment. DETAILED DESCRIPTION
[0037] In order to make the above-mentioned objects, features and advantages of the present invention more obvious and easy to understand, the specific embodiments of the present invention are described in detail below in conjunction with the examples. The lecithin described in the following examples is soybean lecithin, pharmaceutical grade, purity 98%, purchased from McLean; cholesterol is pharmaceutical grade, purity 99%, purchased from McLean. In the description of the present invention, unless otherwise specified, the reagents used are all commercially available.
[0038] Example 1
[0039] The needle tip of the fast-dissolving microneedle patch for improving androgenic alopecia of this embodiment is coated with liposome nanoparticles loaded with ginsenoside CK and nitrosoglutathione, and a mixed solution of a liposome solution loaded with ginsenoside CK and nitrosoglutathione and a polyvinyl alcohol solution is used as the needle tip preparation solution.
[0040] The specific preparation method of the microneedle patch of this embodiment includes the following steps:
[0041] Step 1: pouring polydimethylsiloxane on the positive mold of the microneedle array, and demoulding after curing and molding to obtain a negative mold microneedle array mold corresponding to the positive mold;
[0042] Step 2, dissolving lecithin and cholesterol in a mixed solution of chloroform and anhydrous ethanol, adding ginsenoside CK thereto after fully dissolving, and stirring and dissolving at room temperature to obtain a mixed solution; the concentration of ginsenoside CK in the mixed solution is 2 mg / mL, the concentration of lecithin is 10 mg / mL, the concentration of cholesterol is 2.5 mg / mL, and the volume ratio of chloroform and anhydrous ethanol is 1:1;
[0043] Step 3: Transfer 10 mL of the mixed solution in step 2 to a round-bottom flask, and perform rotary evaporation at 37°C for 15 min to form a uniform light yellow film at the bottom of the round-bottom flask. Then, place the mixture in a vacuum drying oven to evaporate the trace amount of organic solvent. The drying time is 6 h.
[0044] Step 4: dissolving nitrosoglutathione in a PBS solution at pH = 7.4 to obtain a GSNO solution with a concentration of 0.5 mg / mL of nitrosoglutathione; then transferring 10 mL of the GSNO solution to the round-bottom flask dried in step 3, hydrating at 37° C. in the dark for 30 min, ultrasonically treating at 400 W for 5 min after hydration, filtering with a 220 μM filter membrane, centrifuging at 4000 g to remove undissolved ginsenoside CK, and centrifuging with a 1 KDa ultrafiltration centrifuge tube to remove GSNO that did not enter the hydrophilic cavity inside the liposome to obtain a liposome solution loaded with ginsenoside CK and nitrosoglutathione;
[0045] Step 5: Mix the liposome solution loaded with ginsenoside CK and nitrosoglutathione with a polyvinyl alcohol solution having a mass percentage concentration of 25% in a volume ratio of 1:65 to obtain a needle tip preparation solution;
[0046] Step 6: Add the needle tip preparation solution in step 5 to the negative mold microneedle array mold in step 1, and evacuate with a vacuum pump to a vacuum degree of 50 kPa, so that the needle tip preparation solution fully enters the needle tip part of the negative mold microneedle array mold;
[0047] Step 7. Aspirate the excess needle tip preparation liquid except the needle tip, add a polyvinyl alcohol solution with a mass percentage concentration of 25% into the negative mold to fill the remaining part of the mold. The total filling solution volume is 500 μL, and then place it in an oven and dry it at 37°C for 20 hours. Demold to obtain a fast-dissolving microneedle patch that can improve androgenic alopecia.
[0048] Example 2
[0049] The needle tip of the fast-dissolving microneedle patch for improving androgenic alopecia of this embodiment is coated with liposome nanoparticles loaded with ginsenoside CK and nitrosoglutathione, and a mixed solution of a liposome solution loaded with ginsenoside CK and nitrosoglutathione and a polyvinyl alcohol solution is used as the needle tip preparation solution.
[0050] The specific preparation method of the microneedle patch of this embodiment includes the following steps:
[0051] Step 1: pouring polydimethylsiloxane on the positive mold of the microneedle array, and demoulding after curing and molding to obtain a negative mold microneedle array mold corresponding to the positive mold;
[0052] Step 2, dissolving lecithin and cholesterol in a mixed solution of chloroform and anhydrous ethanol, adding ginsenoside CK thereto after fully dissolving, stirring and dissolving at room temperature to obtain a mixed solution; the concentration of ginsenoside CK in the mixed solution is 1 mg / mL, the concentration of lecithin is 5 mg / mL, the concentration of cholesterol is 1 mg / mL, and the volume ratio of chloroform to anhydrous ethanol is 1:2;
[0053] Step 3: Transfer 10 mL of the mixed solution in step 2 to a round-bottom flask, and perform rotary evaporation at 30°C for 30 min to form a uniform light yellow film at the bottom of the round-bottom flask. Then, place the mixture in a vacuum drying oven to evaporate the trace organic solvent for 12 h.
[0054] Step 4: dissolving nitrosoglutathione in a PBS solution at pH = 7.4 to obtain a GSNO solution with a concentration of 0.2 mg / mL of nitrosoglutathione; then transferring 10 mL of the GSNO solution to the round-bottom flask dried in step 3, hydrating for 40 min at 30° C. in the dark, ultrasonically treating for 10 min at 300 W after hydration, filtering with a 220 μM filter membrane, centrifuging at 4000 g to remove undissolved ginsenoside CK, and centrifuging with a 1 KDa ultrafiltration centrifuge tube to remove GSNO that did not enter the hydrophilic cavity inside the liposome to obtain a liposome solution loaded with ginsenoside CK and nitrosoglutathione;
[0055] Step 5: Mix the liposome solution loaded with ginsenoside CK and nitrosoglutathione with a polyvinyl alcohol solution having a mass percentage concentration of 20% in a volume ratio of 1:50 to obtain a needle tip preparation solution;
[0056] Step 6: Add the needle tip preparation solution in step 5 to the negative mold microneedle array mold in step 1, and evacuate with a vacuum pump to a vacuum degree of 70 kPa, so that the needle tip preparation solution fully enters the needle tip part of the negative mold microneedle array mold;
[0057] Step 7. Aspirate the excess needle tip preparation liquid except the needle tip, add a polyvinyl alcohol solution with a mass percentage concentration of 15% to the negative mold to fill the empty part of the mold. The total filling solution volume is 500 μL, and then place it in an oven and dry it at 30°C for 24 hours. Demold to obtain a fast-dissolving microneedle patch that can improve androgenic alopecia.
[0058] Example 3
[0059] The needle tip of the fast-dissolving microneedle patch for improving androgenic alopecia of this embodiment is coated with liposome nanoparticles loaded with ginsenoside CK and nitrosoglutathione, and a mixed solution of a liposome solution loaded with ginsenoside CK and nitrosoglutathione and a polyvinyl alcohol solution is used as the needle tip preparation solution.
[0060] The specific preparation method of the microneedle patch of this embodiment includes the following steps:
[0061] Step 1: pouring polydimethylsiloxane on the positive mold of the microneedle array, and demoulding after curing and molding to obtain a negative mold microneedle array mold corresponding to the positive mold;
[0062] Step 2, dissolving lecithin and cholesterol in a mixed solution of chloroform and anhydrous ethanol, adding ginsenoside CK thereto after fully dissolving, and stirring and dissolving at room temperature to obtain a mixed solution; the concentration of ginsenoside CK in the mixed solution is 4 mg / mL, the concentration of lecithin is 20 mg / mL, the concentration of cholesterol is 5 mg / mL, and the volume ratio of chloroform to anhydrous ethanol is 1:3;
[0063] Step 3: Transfer 10 mL of the mixed solution in step 2 to a round-bottom flask, and perform rotary evaporation at 45°C for 10 min to form a uniform light yellow film at the bottom of the round-bottom flask. Then, place the mixture in a vacuum drying oven to evaporate the trace organic solvent for 4 h.
[0064] Step 4: dissolving nitrosoglutathione in a PBS solution at pH = 7.4 to obtain a GSNO solution with a concentration of 1 mg / mL of nitrosoglutathione; then transferring 10 mL of the GSNO solution to the round-bottom flask dried in step 3, hydrating at 45° C. in the dark for 20 min, ultrasonically treating at 500 W for 2 min after hydration, filtering with a 220 μM filter membrane, centrifuging at 4000 g to remove undissolved ginsenoside CK, and centrifuging with a 1 KDa ultrafiltration centrifuge tube to remove GSNO that did not enter the hydrophilic cavity inside the liposome to obtain a liposome solution loaded with ginsenoside CK and nitrosoglutathione;
[0065] Step 5: Mix the liposome solution loaded with ginsenoside CK and nitrosoglutathione with a polyvinyl alcohol solution having a mass percentage concentration of 30% in a volume ratio of 1:80 to obtain a needle tip preparation solution;
[0066] Step 6: Add the needle tip preparation solution in step 5 to the negative mold microneedle array mold in step 1, and evacuate with a vacuum pump to a vacuum degree of 30 kPa, so that the needle tip preparation solution fully enters the needle tip part of the negative mold microneedle array mold;
[0067] Step 7. Aspirate the excess needle tip preparation liquid except the needle tip, add a polyvinyl alcohol solution with a mass percentage concentration of 35% to the negative mold to fill the empty part of the mold. The total filling solution volume is 500 μL, and then place it in an oven and dry it at 45°C for 12 hours. Demold to obtain a fast-dissolving microneedle patch that can improve androgenic alopecia.
[0068] Figure 1 The present invention is a schematic diagram of the construction and use of a fast-dissolving microneedle patch that can improve androgenic alopecia. The construction process shows that the present invention uses a cell membrane-like phospholipid bilayer structure constructed by lecithin and cholesterol to encapsulate GSNO and ginsenoside CK, wherein GSNO is encapsulated in the hydrophilic cavity inside the liposome as a NO donor, and ginsenoside CK is encapsulated in the hydrophobic layer of the liposome membrane. The prepared liposomes are then locally delivered by microneedles to deliver the drug to the hair loss site to exert its effect. On the basis of improving the solubility and utilization rate of ginsenoside CK, it can also delay the rate of GSNO releasing NO, thereby exerting the effect of the two drugs synergistically improving the treatment of hair loss. The microneedle patch can minimize the damage to the patient's skin during the treatment process, and at the same time, it can accurately deliver the drug to the affected area, thereby improving the utilization rate of the drug.
[0069] Comparative Example 1
[0070] Prepare unloaded liposome solution:
[0071] Dissolve lecithin and cholesterol in a mixed solution of chloroform and anhydrous ethanol, wherein the final concentration of lecithin is 10 mg / mL, the final concentration of cholesterol is 2.5 mg / mL, the ratio of chloroform to anhydrous ethanol is 1:1, and stir and dissolve at room temperature for 1 hour to obtain a mixed solution; 10 mL of the mixed solution is rotary evaporated at 37° C. for 15 minutes in a round-bottom flask to obtain a light yellow film adhering to the round-bottom flask, transfer the round-bottom flask to a vacuum drying oven and dry for 4 to 6 hours, then take it out, add 10 mL of pH=7.4 PBS solution, rotate and hydrate at 37° C. in the dark for 30 minutes, and the hydrated liquid is ultrasonically crushed at 400W for 5 minutes, and then filtered using a 220 μM filter membrane to obtain an unloaded liposome solution, and the sample is stored at 4° C.
[0072] Comparative Example 2
[0073] Preparation of liposome solution loaded with ginsenoside CK
[0074] Dissolve lecithin, cholesterol and ginsenoside CK in a mixed solution of chloroform and anhydrous ethanol, wherein the final concentration of lecithin is 10 mg / mL, the final concentration of cholesterol is 2.5 mg / mL, the final concentration of ginsenoside CK is 2 mg / mL, the ratio of chloroform to anhydrous ethanol is 1:1, and stir and dissolve at room temperature for 1 hour to obtain a mixed solution; 10 mL of the mixed solution is rotary evaporated at 37°C for 15 minutes in a round-bottom flask to obtain a light yellow film adhering to the round-bottom flask, transfer the round-bottom flask to a vacuum drying oven and dry for 4 to 6 hours, then take it out, add 10 mL of pH = 7.4 PBS solution, rotate and hydrate at 37°C in the dark for 30 minutes, the hydrated liquid is ultrasonically crushed at 400W for 5 minutes, and then filtered using a 220μM filter membrane, centrifuged at 4000g to remove undissolved ginsenoside CK, to obtain a liposome solution loaded with ginsenoside CK, and store the sample at 4°C.
[0075] Comparative Example 3
[0076] Preparation of liposome solution loaded with nitrosoglutathione:
[0077] Dissolve lecithin and cholesterol in a mixed solution of chloroform and anhydrous ethanol, wherein the final concentration of lecithin is 10 mg / mL, the final concentration of cholesterol is 2.5 mg / mL, the ratio of chloroform to anhydrous ethanol is 1:1, and stir and dissolve at room temperature for 1 hour to obtain a mixed solution; 10 mL of the mixed solution is rotary evaporated in a round-bottom flask at 37° C. for 15 minutes to obtain a light yellow film adhering to the round-bottom flask, and the round-bottom flask is transferred to a vacuum drying oven and dried for 4 to 6 hours before taking out; GSH was dissolved in a PBS solution with a pH of 7.4 to obtain a GSNO solution with a concentration of 0.5 mg / mL; then 10 mL of the GSNO solution was transferred to the above round-bottom flask, and hydrated at 37°C in a rotating, dark environment for 30 min. The hydrated liquid was ultrasonically crushed at 400 W for 5 min, and then filtered using a 220 μM filter membrane. The GSNO that did not enter the hydrophilic cavity inside the liposome was then centrifuged using a 1 KDa ultrafiltration centrifuge tube to remove the GSNO that did not enter the hydrophilic cavity inside the liposome, to obtain a liposome solution loaded with nitrosoglutathione, and the sample was stored at 4°C.
[0078] Example 4 Performance Test
[0079] Determination of encapsulation efficiency and drug loading:
[0080] Encapsulation efficiency (EE) refers to the percentage of encapsulated ginsenoside CK in the total amount of drug in the liposome suspension.
[0081] Drug loading (LE) refers to the content of ginsenoside CK encapsulated per unit weight or unit volume of liposomes.
[0082] The freshly prepared liposome solution loaded with ginsenoside CK and nitrosoglutathione (hereinafter referred to as Lip@CK / GSNO) was centrifuged at 8000rpm for 20min at 20°C, and the supernatant was collected. The Lip@CK / GSNO sample was destroyed and diluted with methanol and then injected into the analytical column. The concentration of loaded ginsenoside CK was calculated according to the ginsenoside CK standard curve. Finally, the calculation formulas for EE and LE are as follows:
[0083]
[0084] The results are as follows Figure 2 As shown, when the concentration of ginsenoside CK is 1 mg / mL to 4 mg / mL, it can meet the requirements of encapsulation efficiency and drug loading rate at the same time.
[0085] In vitro release of NO and ginsenoside CK:
[0086] Place 5 mL of freshly prepared Lip@CK / GSNO in Example 1 into a dialysis bag with a molecular weight cutoff of 1000 Da. Immerse the dialysis bag in 45 mL of PBS buffer (pH = 7.4) and incubate on a constant temperature shaker at 37°C. Set appropriate sampling time intervals (5 minutes, 10 minutes, 30 minutes, 1 hour, 3 hours, 6 hours, 12 hours, 24 hours, 36 hours, 48 hours). After fully shaking, take 5 mL of release solution from the centrifuge tube and immediately add an equal volume of fresh PBS buffer. The NO released in the solution is mixed with the Griess reagent and incubated in the dark for 15 minutes. Measure the absorbance at 540 nm, and use the NO standard curve to calculate the cumulative percentage of NO release. Each sample was run in triplicate, and the results were expressed as the mean and standard deviation. The remaining samples were tested for the content of ginsenoside CK by high performance liquid chromatography, and the cumulative percentage of ginsenoside CK release was calculated using the ginsenoside CK standard curve. Each sample was run in triplicate, and the results were expressed as the mean and standard deviation. The results are shown in Figure 2. Figure 3 As shown, the ginsenoside CK of Example 1 can reach the maximum release within 48 hours, and the nitrosoglutathione can reach the maximum release within 12 hours.
[0087] Particle size and morphology characteristics of liposome nanoparticles:
[0088] 5 mL of the freshly prepared Lip@CK / GSNO in Example 1 was taken out and filtered, and then its particle size was analyzed using a Nicomp N3000 dynamic light scattering nanoparticle size analyzer. The results are as follows: Figure 4 As shown, the average particle size of liposome nanoparticles is about 100 nm, and after encapsulating different drugs, the particle size does not change much, and the liposome nanoparticles have uniform morphology and a size that is consistent with the particle size test results.
[0089] Microneedle morphology features:
[0090] Figure 5 A is a schematic diagram of the morphology of the microneedle patch under a scanning electron microscope (SEM), and the picture shows that each needle tip of the microneedle patch is uniform. B is a schematic diagram of the morphology of the microneedle patch under a confocal laser scanning microscope (CLSM) and the loading of drugs. The picture shows that the microneedles are uniformly loaded with liposome nanoparticles containing rhodamine B. C and D are schematic diagrams of the morphology of the microneedle patch at different angles and magnifications, respectively, which are consistent with the morphology observed by electron microscopy.
[0091] Cytotoxicity assay:
[0092] HFDPC cells were cultured in a specific culture medium and placed in a biochemical incubator at 37°C and 5% CO2. Cells with good growth and a cell density of more than 80% were taken, digested with trypsin, collected, centrifuged, and counted. According to the results obtained, the cell density was adjusted to 5000 cells / mL, added to a 96-well plate, with a volume of 100 μL per well, and placed in a 37°C incubator for culture. After 24 hours, the supernatant was discarded, and different drugs were added according to the control group, DHT, Lip@GSNO, Lip@CK, Lip@CK / GSNO, and UV. The control group was added with an equal volume of culture medium, and the model group was added with the corresponding concentration of DHT. Five replicates were set for each concentration. CCK-8 reagent was added to the 96-well plate (10 μL per well) at 24 hours, 48 hours, and 72 hours respectively, and cultured for 4 hours. Then the absorbance was measured at 450nm by an enzyme reader, and the cytotoxicity was calculated using the formula.
[0093]
[0094] like Figure 6 It showed that ginsenoside CK had no toxicity at a concentration of less than 4 μM, and ginsenoside CK and GSNO had a synergistic effect in promoting proliferation of the HFDPC cell model constructed by DHT.
[0095] Therapeutic effects of androgenic alopecia
[0096] Thirty female C57BL / 6 mice (6-8 weeks old, average weight 20g) were prepared and kept at room temperature of 22℃~24℃, relative humidity of 60%, and 12h light / dark cycle throughout the experimental period. Each group of experimental mice was guaranteed to have enough food and water, and the mice were allowed to adapt to the experimental environment for one week before the experiment. After depilatory cream was used, DHT was subcutaneously injected to induce the male mouse model. The dose was 10mg / kg·d. The same dose of DHT was continuously injected throughout the treatment to maintain the androgen level in the body. The successful establishment of the model was confirmed by dermoscopy and histopathological sections.
[0097] Using the liposome solutions prepared in Comparative Examples 1 to 3, three microneedle patches with different compositions were prepared according to the microneedle preparation method in Example 1, namely MN, MN-CK and MN-GSNO groups, and the microneedle patch prepared in Example 1 was used as the MN-CK / GSNO group. The four groups of mouse models were treated separately, and starting from the first day, the MN group, MN-CK group, MN-GSNO group, and MN-CK / GSNO group were treated with corresponding microneedle patches for 28 days. The growth of the hair on the back of the mice was tracked and photographed on the 7th, 14th, 21st and 28th days, and a dermatoscope was used for further local observation and recording, and the weight of the mice, changes in the color of the back skin and hair growth were recorded in detail. The results are as follows: Figure 7As shown, the hair coverage of the MN group was very poor at 10 days, while the MN-CK group and the MN-GSNO group were better than the MN group, but the coverage rate was less than 20%, while the hair coverage of the MN-CK / GSNO group increased significantly. At 20 days, the hair coverage of the MN group was still not obvious, while the MN-CK group and the MN-GSNO group were significantly improved, with a coverage rate of 50% to 60%, and the MN-CK / GSNO group had the best effect, reaching 90%. This proves that the microneedle patch loaded with both CK and GSNO can effectively improve androgenic alopecia and achieve good therapeutic effects.
[0098] After the experiment, the back skin tissues of healthy mice, mouse models and the above groups of mice were taken, fixed with 4% paraformaldehyde solution, embedded in paraffin, and cut into 5 μm thick slices after solidification. The slices were stained with H&E, and the hair follicles in the skin tissue were observed under an optical microscope. Image J software was used to measure the hair diameter and total number of hair follicles in each group. The results are shown in Figure 2. Figure 8 and Fig. 9 As shown in the figure, the HE section results show that the hair follicles of the mouse model are severely damaged compared with healthy mice, and each treatment group has different degrees of improvement, among which the MN-CK / GSNO group has the best treatment effect. Each treatment group showed a certain ability to regenerate hair, among which the MN-CK / GSNO group had regenerated hair with a larger diameter.
[0099] The five internal organs of each group of mice were sliced and tested. The results were as follows: Fig.10 As shown, it can be seen from the figure that the microneedle patch of the present invention has no physiological toxicity.
[0100] The fast-dissolving microneedle patch for improving androgenic alopecia of the present invention is a powerful transdermal drug delivery system. The needle tip of the microneedle patch is coated with liposome nanoparticles loaded with ginsenoside CK and nitrosoglutathione. The needle tip can penetrate the epidermis and transport the drug to a certain skin depth. In addition, penetration less than 750 μM hardly causes bleeding or pain, which meets the basic drug delivery needs while reducing the patient's pain. The needle tip of the microneedle patch can reach the interstitial fluid, dissolve quickly and then slowly release ginsenoside CK and GSNO to reach the microenvironment of the hair papilla cells to play a role, improve the hair follicle microenvironment, remove excess ROS in the hair follicle microenvironment, promote angiogenesis, and increase the activity of hair papilla cells that play a key role in androgenic alopecia. It is expected to be used in the preparation of drugs and / or medical devices for improving the hair follicle microenvironment.
[0101] The above description is only a preferred embodiment of the present invention and does not limit the present invention in any way. Any simple modification, change and equivalent structural change made to the above embodiment according to the technical essence of the invention still falls within the protection scope of the technical solution of the present invention.
Claims
1. A fast-dissolving microneedle patch for improving androgenic alopecia, characterized in that: The needle tip of the microneedle patch is coated with liposome nanoparticles loaded with ginsenoside CK and nitrosoglutathione.
2. A fast-dissolving microneedle patch for improving androgenic alopecia according to claim 1, characterized in that: When the needle tip is coated with liposome nanoparticles loaded with ginsenoside CK and nitrosoglutathione, a mixed solution of a liposome solution loaded with ginsenoside CK and nitrosoglutathione and a polyvinyl alcohol solution is used as the needle tip preparation solution.
3. A method for preparing the fast-dissolving microneedle patch for improving androgenic alopecia as claimed in claim 1 or 2, characterized in that: The following steps are involved: Step 1, preparing a negative microneedle array mold; Step 2, after dissolving lecithin and cholesterol, add ginsenoside CK to obtain a mixed solution; the concentration of ginsenoside CK in the mixed solution is 1 mg / mL to 4 mg / mL; the concentration of lecithin is 5 mg / mL to 20 mg / mL, and the concentration of cholesterol is 1 mg / mL to 5 mg / mL; Step 3, transferring the mixed solution in step 2 into a round-bottom flask, rotary evaporating until a uniform film is formed at the bottom of the round-bottom flask, and then drying to evaporate trace amounts of organic solvent; Step 4, dissolving nitrosoglutathione in PBS solution to obtain GSNO solution; then transferring the GSNO solution to the round-bottom flask dried in step 3 and hydrating in the dark, ultrasonically treating after hydration, filtering and centrifuging to remove undissolved ginsenoside CK and nitrosoglutathione that did not enter the hydrophilic cavity inside the liposome, and obtaining a liposome solution loaded with ginsenoside CK and nitrosoglutathione; Step 5, mixing the liposome solution loaded with ginsenoside CK and nitrosoglutathione with the polyvinyl alcohol solution to obtain a needle tip preparation solution; Step 6: Add the needle tip preparation solution in step 5 to the negative mold microneedle array mold in step 1, and use a vacuum pump to evacuate the mold so that the needle tip preparation solution fully enters the needle tip portion of the negative mold microneedle array mold; Step 7: Suck out the excess needle tip preparation liquid except the needle tip, add polyvinyl alcohol solution to the negative mold to fill the empty part of the mold, then place it in an oven to dry, and demold to obtain a fast-dissolving microneedle patch that can improve androgenic alopecia.
4. The method according to claim 3, characterized in that In step 2, lecithin and cholesterol are dissolved in a mixed solution of chloroform and anhydrous ethanol, and the volume ratio of chloroform to anhydrous ethanol is 1:(1-3).
5. The method according to claim 3, characterized in that: In step 3, the temperature of the rotary evaporation is 30° C. to 45° C., the duration is 10 min to 30 min, and the vacuum drying oven is used for drying, and the drying time is 4 h to 12 h.
6. The method according to claim 3, characterized in that The concentration of nitrosoglutathione in the GSNO solution in step 4 is 0.2 mg / mL to 1 mg / mL; the hydration condition is 30° C. to 45° C. for 20 min to 40 min; the ultrasonic time is 2 min to 10 min, the ultrasonic power is 300 W to 500 W, and the filtration is performed using a 220 μM filter membrane.
7. The method according to claim 3, characterized in that The mass percentage concentration of the polyvinyl alcohol solution in step five is 20% to 30%; the volume ratio of the liposome solution loaded with ginsenoside CK and nitrosoglutathione to the polyvinyl alcohol solution is 1:(50 to 80).
8. The method according to claim 3, characterized in that In step six, the vacuum degree is 30 kPa to 70 kPa.
9. The method according to claim 3, characterized in that: In step seven, the total filling solution volume is 500 μL; the oven temperature is 30° C. to 45° C., and the drying time is 12 h to 24 h.
10. Use of the fast-dissolving microneedle patch capable of improving androgenic alopecia as claimed in claim 1 or 2 in the preparation of drugs and / or medical devices for improving the hair follicle microenvironment.
Citation Information
Patent Citations
Nano lipid carrier microneedle for treating alopecia and application of nano lipid carrier microneedle
CN111329832A
Soluble microneedle for promoting hair growth and preparation method
CN111544573A
Rapid separation type liposome composite sustained-release microneedle and preparation method thereof
CN114569583A
Application of ginsenoside CK as medicine for treating alopecia seborrhoeica
CN116440145A
Enhanced nitric oxide delivery and uses thereof
US20130084336A1
Cited By
Micro-needle patch for targeted treatment of acnes and prevention of formation of acne scars and application of micro-needle patch
CN121041200A
